01302.HK
LifeTech Scientific Corporation
HKSE · Healthcare · Medical - Devices · CN
HKD 1.47
−5.16%Oct 30, 2026, 04:33 UTC
Yuanxin Technology said its IBS bioabsorbable drug-eluting coronary stent system received EU CE MDR certification, making it the first iron-based coronary stent system to receive sales authorization.
Source:Oct 21, 2026, 01:52 UTC
China’s LifeTech Scientific Corp. confirmed that LifeTech Scientific Corp.’s ICS Elpis bioabsorbable peripheral covered stent system entered its special review program for innovative medical devices.
Source:Sep 25, 2026, 02:44 UTC
China's National Medical Products Administration accepted Hansoh Pharmaceutical's marketing application for its self-developed HS-20093 (recombinant anti-B7-H3 antibody-drug conjugate) injection for the treatment of osteosarcoma in patients aged 12 or older who failed at least two prior lines of therapy.
Source:Sep 25, 2026, 02:32 UTC
China's National Medical Products Administration confirmed that Lifetech Scientific's SureCham single-branch aortic arch stent graft system, co-developed with Professor Shu Chang's team at Fuwai Hospital of the Chinese Academy of Medical Sciences, entered the special review procedure for innovative medical devices.
Source:Jul 21, 2026, 01:17 UTC
Lifetech Scientific announced the termination of its proposed acquisition of Huayi Medical equity and the related convertible bond issuance, after negotiations failed to reach an agreement.
Source: